Recurrent hepatocellular carcinoma after liver transplant: Identifying the high-risk patient

Nicholas N. Nissen, Vijay Menon, Catherine Bresee, Tram T. Tran, Alagappan Annamalai, Fred Poordad, Jeffrey H. Fair, Andrew S. Klein, Brendan Boland, Steven D Colquhoun

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver Disease (MELD) tumour exception policies. Results: Liver transplantation was performed in 122 patients with HCC during this period. Rates of recurrence-free survival in the entire cohort at 1 year and 3 years were 95% and 89%, respectively. Thirteen patients developed HCC recurrence at a median of 14 months post-LT. In univariate analysis the factors associated with HCC recurrence were bilobar tumours, vascular invasion, and stage exceeding either Milan or University of California San Francisco (UCSF) Criteria. Multivariate analysis showed pathology outside UCSF Criteria was the major predictor of recurrence; when pathology outside UCSF Criteria was found in combination with vascular invasion, the predicted 3-year recurrence-free survival was only 26%. Conclusions: Explant pathology can be used to predict the risk for recurrent HCC after LT, which may allow for improved adjuvant and management strategies.

Original languageEnglish (US)
Pages (from-to)626-632
Number of pages7
JournalHPB
Volume13
Issue number9
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Liver Transplantation
Transplants
Recurrence
Liver
San Francisco
Pathology
Blood Vessels
Neoplasms
End Stage Liver Disease
Survival
Statistical Factor Analysis
Multivariate Analysis

Keywords

  • hepatocellular carcinoma
  • indications < transplant
  • liver < transplant
  • outcomes < transplant

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Recurrent hepatocellular carcinoma after liver transplant : Identifying the high-risk patient. / Nissen, Nicholas N.; Menon, Vijay; Bresee, Catherine; Tran, Tram T.; Annamalai, Alagappan; Poordad, Fred; Fair, Jeffrey H.; Klein, Andrew S.; Boland, Brendan; Colquhoun, Steven D.

In: HPB, Vol. 13, No. 9, 01.01.2011, p. 626-632.

Research output: Contribution to journalArticle

Nissen, NN, Menon, V, Bresee, C, Tran, TT, Annamalai, A, Poordad, F, Fair, JH, Klein, AS, Boland, B & Colquhoun, SD 2011, 'Recurrent hepatocellular carcinoma after liver transplant: Identifying the high-risk patient', HPB, vol. 13, no. 9, pp. 626-632. https://doi.org/10.1111/j.1477-2574.2011.00342.x
Nissen NN, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F et al. Recurrent hepatocellular carcinoma after liver transplant: Identifying the high-risk patient. HPB. 2011 Jan 1;13(9):626-632. https://doi.org/10.1111/j.1477-2574.2011.00342.x
Nissen, Nicholas N. ; Menon, Vijay ; Bresee, Catherine ; Tran, Tram T. ; Annamalai, Alagappan ; Poordad, Fred ; Fair, Jeffrey H. ; Klein, Andrew S. ; Boland, Brendan ; Colquhoun, Steven D. / Recurrent hepatocellular carcinoma after liver transplant : Identifying the high-risk patient. In: HPB. 2011 ; Vol. 13, No. 9. pp. 626-632.
@article{169cc28957a545c28600407a6efcfe5f,
title = "Recurrent hepatocellular carcinoma after liver transplant: Identifying the high-risk patient",
abstract = "Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver Disease (MELD) tumour exception policies. Results: Liver transplantation was performed in 122 patients with HCC during this period. Rates of recurrence-free survival in the entire cohort at 1 year and 3 years were 95{\%} and 89{\%}, respectively. Thirteen patients developed HCC recurrence at a median of 14 months post-LT. In univariate analysis the factors associated with HCC recurrence were bilobar tumours, vascular invasion, and stage exceeding either Milan or University of California San Francisco (UCSF) Criteria. Multivariate analysis showed pathology outside UCSF Criteria was the major predictor of recurrence; when pathology outside UCSF Criteria was found in combination with vascular invasion, the predicted 3-year recurrence-free survival was only 26{\%}. Conclusions: Explant pathology can be used to predict the risk for recurrent HCC after LT, which may allow for improved adjuvant and management strategies.",
keywords = "hepatocellular carcinoma, indications < transplant, liver < transplant, outcomes < transplant",
author = "Nissen, {Nicholas N.} and Vijay Menon and Catherine Bresee and Tran, {Tram T.} and Alagappan Annamalai and Fred Poordad and Fair, {Jeffrey H.} and Klein, {Andrew S.} and Brendan Boland and Colquhoun, {Steven D}",
year = "2011",
month = "1",
day = "1",
doi = "10.1111/j.1477-2574.2011.00342.x",
language = "English (US)",
volume = "13",
pages = "626--632",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Recurrent hepatocellular carcinoma after liver transplant

T2 - Identifying the high-risk patient

AU - Nissen, Nicholas N.

AU - Menon, Vijay

AU - Bresee, Catherine

AU - Tran, Tram T.

AU - Annamalai, Alagappan

AU - Poordad, Fred

AU - Fair, Jeffrey H.

AU - Klein, Andrew S.

AU - Boland, Brendan

AU - Colquhoun, Steven D

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver Disease (MELD) tumour exception policies. Results: Liver transplantation was performed in 122 patients with HCC during this period. Rates of recurrence-free survival in the entire cohort at 1 year and 3 years were 95% and 89%, respectively. Thirteen patients developed HCC recurrence at a median of 14 months post-LT. In univariate analysis the factors associated with HCC recurrence were bilobar tumours, vascular invasion, and stage exceeding either Milan or University of California San Francisco (UCSF) Criteria. Multivariate analysis showed pathology outside UCSF Criteria was the major predictor of recurrence; when pathology outside UCSF Criteria was found in combination with vascular invasion, the predicted 3-year recurrence-free survival was only 26%. Conclusions: Explant pathology can be used to predict the risk for recurrent HCC after LT, which may allow for improved adjuvant and management strategies.

AB - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver Disease (MELD) tumour exception policies. Results: Liver transplantation was performed in 122 patients with HCC during this period. Rates of recurrence-free survival in the entire cohort at 1 year and 3 years were 95% and 89%, respectively. Thirteen patients developed HCC recurrence at a median of 14 months post-LT. In univariate analysis the factors associated with HCC recurrence were bilobar tumours, vascular invasion, and stage exceeding either Milan or University of California San Francisco (UCSF) Criteria. Multivariate analysis showed pathology outside UCSF Criteria was the major predictor of recurrence; when pathology outside UCSF Criteria was found in combination with vascular invasion, the predicted 3-year recurrence-free survival was only 26%. Conclusions: Explant pathology can be used to predict the risk for recurrent HCC after LT, which may allow for improved adjuvant and management strategies.

KW - hepatocellular carcinoma

KW - indications < transplant

KW - liver < transplant

KW - outcomes < transplant

UR - http://www.scopus.com/inward/record.url?scp=80051915645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051915645&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2011.00342.x

DO - 10.1111/j.1477-2574.2011.00342.x

M3 - Article

C2 - 21843263

AN - SCOPUS:80051915645

VL - 13

SP - 626

EP - 632

JO - HPB

JF - HPB

SN - 1365-182X

IS - 9

ER -